ArticlePloS one2024

Adverse events analysis of Relugolix (Orgovyx®) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS).

Ruibo Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.